The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1541
The full issue is available to subscribers Subscriber Login   
Benralizumab (Fasenra) for Severe Eosinophilic Asthma
Revised 5/1/18: Information in the Dosage section regarding hypersensitivity reactions was revised.

The FDA has approved benralizumab (Fasenra – AstraZeneca), a humanized monoclonal antibody selective for the interleukin-5 (IL-5) receptor, for add-on maintenance treatment of severe asthma in patients ≥12 years old with an eosinophilic phenotype. Benralizumab is the third anti-IL-5 antibody to be approved for treatment of severe eosinophilic asthma; mepolizumab (Nucala) and reslizumab (Cinqair), which target IL-5 itself, were approved earlier.1,2

MECHANISM OF ACTION — Severe asthma often has an eosinophilic phenotype with elevated blood and lung eosinophil levels.3,4 IL-5 is the major cytokine responsible for the growth, differentiation, recruitment, activation, and survival of eosinophils. Mepolizumab and reslizumab, the two previously approved anti-IL-5 antibodies, reduce the production and survival ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1541
Select version:
 Downloadable, electronic issue - $45
 Postal, hardcopy issue - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian